Dr Mark Hill

Professional statement

Dr Mark Hill is an esteemed consultant medical oncologist based in Maidstone. With over 35 years of experience, he specialises in colorectal cancer, immunotherapy, chemotherapy, antibody therapy, personalised medicine and molecular targeting.

Dr Hill qualified in medicine from the University of London in 1986 before going on to pursue specialist training in medical oncology at Guy’s Hospital. He attained membership of the Royal College of Physicians in 1989 and was awarded a highly sought-after clinical fellowship with the Cancer Research Campaign in 1991. During this period, he undertook research into molecularly targeted cancer treatment in clinical and laboratory settings. In recognition of the excellence of his research, he was awarded an MD from the University of London in 1996. Several years later, Dr Hill completed his clinical training at the Royal Marsden Hospital and was appointed as a consultant medical oncologist. In 2003, he was awarded fellowship of the Royal College of Physicians and the position of lead medical oncologist of the Kent Cancer Network. Dr Hill currently serves as clinical director of the Kent, Surrey, and Sussex Clinical Research Network and as a consultant medical oncologist with the Maidstone and Tunbridge Wells NHS Foundation Trust. He also sees private patients at GenesisCare Maidstone and the Kent Oncology Centre.

Additional to his clinical responsibilities, Dr Hill also serves as a founding trustee of the Kent Cancer Trust and sits on the National Cancer Research Institute’s advanced colon cancer trials sub-committee. He has also held the position of honorary senior lecturer at the University of Kent since 2004. Dr Hill has published extensively in academic journals and remains actively involved in research as a principal investigator. He is closely involved with numerous clinical trials relating to innovative treatment approaches, in which many of his patients take part. Throughout his career, Dr Hill’s work has been recognised with a number of prizes, including a research award from the Royal College of Physicians in 2018. He is a member of various professional organizations, including the American Society of Clinical Oncology, the Association of Cancer Physicians, and the European Society for Medical Oncology.